Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
431 stopped studies mapped to Urinary System Carcinoma and descendants · 87% state a reason
Over the 431 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC…(PREPARE) | Phase 3 | terminated | Jan 9, 2017 | AIO-Studien-gGmbH | insufficient accrual rate | Enrollment / accrual |
| NCT05534789 | Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell… | — | terminated | Sep 10, 2022 | Pfizer | The trial prematurely terminated due to the inability to recruit the planned number of… | Safety / toxicity |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jun 18, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial… | Phase 2 | terminated | Sep 5, 2017 | Arjun Balar, MD | Funder decision | Other (stated, no rule matched) |
| NCT04228042 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | Phase 1 / Phase 2 | terminated | Jan 14, 2020 | M.D. Anderson Cancer Center | Drug manufacturer made the business decision to cease all infigratinib oncology research in the US… | Drug supply |
| NCT04871529 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and… | Phase 2 | terminated | May 4, 2021 | SWOG Cancer Research Network | inability to accrue sufficient patients | Enrollment / accrual |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Phase 2 | withdrawn | Aug 21, 2019 | MedPacto, Inc. | Changing trial strategy | Sponsor / business decision |
| NCT05119010 | A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in…(KETOREIN) | N/A | terminated | Nov 12, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Recruitment challenges: competition with another microbiome trial, patient refusal to join a… | Enrollment / accrual |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | Phase 2 | terminated | Feb 24, 2023 | ImaginAb, Inc. | Strategic decision | Sponsor / business decision |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT03486197 | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced… | Phase 2 | terminated | Apr 3, 2018 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage… | Phase 1 / Phase 2 | terminated | Jan 9, 2018 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK… | Phase 2 | withdrawn | Oct 9, 2020 | M.D. Anderson Cancer Center | A study with 0 ACTUAL Enrollment must have Overall Recruitment Status specified as Withdrawn | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | Phase 4 | terminated | Jan 29, 2019 | Indiana University | Study stopped due to staffing issues that impacted ability to recruit. | Enrollment / accrual |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has… | Phase 2 | withdrawn | May 22, 2024 | EMD Serono Research & Development Institute, Inc. | Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No… | Enrollment / accrual |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint… | Phase 1 | terminated | Dec 7, 2022 | SLK Kliniken Heilbronn GmbH | Premature discontinuation due to üoor participant recruitment | Enrollment / accrual |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell… | Phase 2 | terminated | Jun 11, 2018 | Roberto Pili | Funder halted development of compound in this disease | Other (stated, no rule matched) |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline… | Phase 2 | withdrawn | Oct 10, 2022 | AdventHealth | PI Decision based on no enrollment | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | Phase 1 | withdrawn | Feb 21, 2023 | Insel Gruppe AG, University Hospital Bern | IMP security Issues reported by Sponsor | Other (stated, no rule matched) |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have… | Phase 2 | terminated | May 29, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03905889 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Phase 1 | terminated | Apr 5, 2019 | Brown University | Funding withdrawn | Funding |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder…(ATLAS) | Phase 3 | terminated | Dec 30, 2020 | UroGen Pharma Ltd. | Alternate approach pursued | Other (stated, no rule matched) |
| NCT02542202 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent… | N/A | terminated | Sep 4, 2015 | University of Chicago | due to slow enrollment | Enrollment / accrual |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic…(ERICA) | Phase 2 | terminated | Jun 19, 2018 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving…(OPTIMISE) | — | terminated | May 4, 2017 | Pfizer | The study was terminated early due to the inability to recruit the planned number of patients | Enrollment / accrual |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell… | Phase 1 | terminated | Jun 12, 2020 | Abramson Cancer Center at Penn Medicine | failure to accrue | Enrollment / accrual |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or… | Phase 2 | terminated | Apr 22, 2024 | Fundacion Oncosur | The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive… | Other (stated, no rule matched) |
| NCT03915405 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Phase 1 | terminated | Apr 16, 2019 | Kyowa Kirin, Inc. | Termination was based on the business decision | Sponsor / business decision |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People… | — | terminated | Jan 26, 2023 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in… | Phase 1 | withdrawn | Jun 8, 2023 | Weill Medical College of Cornell University | Insufficient funding | Funding |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | May 25, 2016 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial…(PROOF302) | Phase 3 | terminated | Dec 13, 2019 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development.… | Safety / toxicity |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for…(CANUCK-01) | Phase 2 | withdrawn | Aug 30, 2023 | CHU de Quebec-Universite Laval | Results of EV302 study do not make it feasible to complete a study in second line avelumab… | Other (stated, no rule matched) |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint… | — | terminated | Oct 17, 2018 | Vanderbilt University Medical Center | Study terminated due to unmet targeted accrual goals with only 2 subjects accrued out of 80 planned… | COVID-19 / pandemic |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 14, 2025source: clinicaltrials